← All trials
NCT05977140
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2023
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2024
- First posted
- Aug 4, 2023
- Last posted
- Oct 31, 2023
- Enrollment
- 56
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cocrystal Pharma, Inc.Lead sponsor
- Cocrystal Pharma Australia Pty Ltd.Collaborator
- Nucleus Network LtdOverall official - principal investigator
- Scientia Clinical Research Limited SydneyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.